Brodalumab (Lumicef®) is a human monoclonal immunoglobulin G antibody that is being developed by Kyowa Hakko Kirin in Japan, where it has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. Brodalumab binds with high affinity to interleukin (IL)-17 receptor A, thereby inhibiting several pro-inflammatory cytokines from the IL-17 family. Regulatory applications for brodalumab in plaque psoriasis are also under review in the USA, EU and Canada. This article summarizes the milestones in the development of brodalumab leading to this first approval for the treatment of psoriasis.
KeywordsUstekinumab Dermatology Life Quality Index Clinical Disease Activity Index Nasopharyngitis Dermatology Life Quality Index Score
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Sarah Greig is a salaried employee of Adis, Springer SBM.
- 3.Kyowa Hakko Kirin. Lumicef® approved in Japan [media release]. 4 July 2016. http://www.kyowa-kirin.com.
- 4.Kyowa Hakko Kirin Co. Ltd. Lumicef® subcutaneous injection 210 mg syringe: brodalumab (gene recombination) formulation: Japanese prescribing information. 2016. http://www.kksmile.com. Accessed 5 Aug 2016.
- 5.Valeant Pharmaceuticals International. Valeant announces FDA acceptance of BLA submission for brodalumab in moderate-to-severe plaque psoriasis [media release]. 25 Jan 2016. http://www.valeant.com.
- 7.FirstWord Pharma. FDA advisory panel backs Valeant’s psoriasis drug brodalumab, with suicide risk-mitigation plan [media release]. 19 July 2016. http://www.firstwordpharma.com.
- 8.Kyowa Hakko Kirin Co Ltd. Kyowa Hakko Kirin announces results of the phase 3 studies of KHK4827 in subjects with psoriasis in Japan [media release]. 23 July 2015. http://www.kyowa-kirin.com.
- 9.Amgen, AstraZeneca. Amgen and AstraZeneca announce collaboration to jointly develop and commercialize clinical-stage inflammation portfolio [media release]. 2 Apr 2012. http://www.astrazeneca.com.
- 10.Amgen. Amgen to terminate participation in co-development and commercialization of brodalumab [media release]. 22 May 2015. http://www.amgen.com.
- 11.AstraZeneca. AstraZeneca PLC H1 2015 results [media release]. 30 July 2015. http://www.astrazeneca.com.
- 12.Valeant Pharmaceuticals International. Valeant and AstraZeneca to partner on brodalumab [media release]. 1 Sep 2015. http://www.valeant.com.
- 13.AstraZeneca. AstraZeneca enters licensing agreements with LEO Pharma in skin diseases [media release]. 1 July 2016. http://www.astrazeneca.com.
- 14.Valeant Pharmaceuticals International. Valeant Pharmaceuticals announces new licensing arrangement for brodalumab in Europe [media release]. 1 July 2016. http://www.valeant.com.
- 15.Amgen. Form 10-K [media release]. 19 Feb 2016. http://investors.amgen.com.
- 17.Salinger DH, Endres CJ, Martin DA, et al. A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study. Clin Pharmacol Drug Dev. 2014;3(4):276–83.CrossRefPubMedGoogle Scholar
- 20.Nakagawa H, Niiro H, Ootaki K. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016;81(1):44–52.CrossRefPubMedGoogle Scholar
- 22.Yamasaki K, Nakagawa H. Clinical efficacy and safety of brodalumab (KHK4827), antiinterleukin-17-receptor a monoclonal antibody, in Japanese patients with pustular psoriasis (generalized) and psoriatic erythroderma: a phase 3, open-label, long-term study (4827-004 study) [abstract no. 365 plus poster]. J Am Acad Dermatol. 2015;72(5 Suppl 1):AB228.Google Scholar
- 23.Nakagawa H, Ootaki K. Long-term efficacy and safety of brodalumab in Japanese patients with plaque psoriasis (psoriasis vulgaris, psoriatic arthritis), pustular psoriasis (generalized) and psoriatic erythroderma: an open-label extension study [abstract no. P142]. J Eur Acad Dermatol Venereol. 2016;30(S6):72.Google Scholar
- 26.Strober B, Gordon K, Augustin M, et al. Improvements in patient-reported outcomes (PROs) among moderate to severe plaque psoriasis patients treated with brodalumab: results from AMAGINE-1 [abstract no. 3169]. J Am Acad Dermatol. 2016;74(5 Suppl 1):AB256.Google Scholar
- 27.Paul C, Barker J, Klekotka P, et al. Improvements in health-related quality of life measured by SF-36 and EQ-5D in patients with moderate to severe plaque psoriasis treated with brodalumab [abstract no. 3172]. J Am Acad Dermatol. 2016;74(5 Suppl 1):AB256.Google Scholar
- 29.Papp K, Leonardi C, Menter A, et al. Maintenance of clinical response with long-term brodalumab (AMG 827) therapy for psoriasis: week 144 results from an open-label extension study [abstract no. 956]. J Am Acad Dermatol. 2015;72(5 Suppl 1):AB240.Google Scholar
- 33.Mease P, Genovese MC, Greenwald MW, et al. Two-year clinical response to brodalumab, an anti-IL-17 receptor antibody, in patients with psoriatic arthritis [abstract no. OP0175]. Ann Rheum Dis. 2015;74(Supplement 2):136–7.Google Scholar